Mm’s plus we don’t know how much the market played it’s role one of the worse days in months, also not only does imun have stake in cytocom there’s the 400 mill, I did reach out to imun about what value cytocom brings to us as shareholders
To alans2354@yahoo.com Oct 28 at 1:04 PM You've got a new message Alan Thank you for your inquiry. Let me try to answer your questions: Immune owns an equity stake in Cytocom. Like any equity investor, Immune would benefit from Cytocom based on the performance of the new merged company shares. View it as an asset of Immune. Immune licensed its rights in certain technologies to Immune.